Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles
Abstract
Receptor-mediated delivery of hydrophobic antitumor drugs is of great interest in chemotherapy of tumors such as glioma. Specific expression of interleukin-13 (IL-13) receptor has been characterized in glioma. In this work, a specific peptide corresponding to the residues within IL-13 protein, designated as IP, was exploited, for the first time, as a glioma-targeting ligand. IP was conjugated to mesoporous silica nanoparticles (MSN) via bifunctional polyethyleneglycol (PEG), constructing the vector MSN–PEG–IP. The successful synthesis of MSN–PEG–IP was demonstrated via Fourier transform infrared spectroscopy. The transmission electron microscopy result showed that the size of MSN–PEG–IP was about 160 nm with an average pore diameter of around 2.6 nm. The cellular uptake of doxorubicin (DOX)-loading IP-modified system (MSN–PEG–IP/DOX) was concentration-dependent in glioma U251 cells. IP modification could significantly enhance the cellular uptake of the drug delivery system in U251 cells but not in normal astrocyte 1800 cells, compared to unmodified counterparts. This effect was further verified by cytotoxicity analysis. Furthermore, the intracellular trafficking result indicated that the loaded DOX was mostly accumulated in nuclei, even at very short incubation time (5 min). All the results suggested that IP could be applied as a special glioma-targeting ligand, and MSN–PEG–IP is a potential vector for delivering hydrophobic chemotherapeutic drugs to IL-13 receptor-overexpressed tumors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IP-modified MSN delivering doxorubicin significantly increases drug uptake by U251 cells and accumulates in the nucleus, enhancing targeting.
“For the first time, Wang et al. used IP as a glioma targeting ligand to modify MSN, as a new type of carrier to deliver doxorubicin, which can significantly increase drug uptake by U251 cells and accumulate in the nucleus, enhanced targeting.226”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [226]
Cites
Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery
Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S. G., Nel, A. E., Tamanoi, F., & Zink, J. I. (2008) · ACS Nano · doi:10.1021/nn800072t · Cited by 1,932 · see citing works
Du, J., Du, X., Mao, C., & Wang, J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja207150n · Cited by 1,177 · see citing works
Lu, J., Liong, M., Li, Z., Zink, J. I., & Tamanoi, F. (2010) · Small · doi:10.1002/smll.201000538 · Cited by 1,075 · see citing works
Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs
Lu, J., Liong, M., Zink, J. I., & Tamanoi, F. (2007) · Small · doi:10.1002/smll.200700005 · Cited by 1,012 · see citing works
Pan, L., He, Q., Liu, J., Chen, Y., Ma, M., Zhang, L., & Shi, J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211035w · Cited by 985 · see citing works
Rosenholm, J. M., Sahlgren, C., & Lindén, M. (2010) · Nanoscale · doi:10.1039/c0nr00156b · Cited by 572 · see citing works
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566 · see citing works
Huang, R., Qu, Y., Ke, W., Zhu, J., Pei, Y., & Jiang, C. (2007) · The FASEB Journal · doi:10.1096/fj.06-7380com · Cited by 311 · see citing works
Self-citationTaratula, O., Garbuzenko, O. B., Chen, A. M., et al. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.622404 · Cited by 245 · see citing works
Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I. H., & Puri, R. K. (1995) · PubMed · Cited by 216 · see citing works
Han, L., Huang, R., Li, J., Liu, S., Huang, S., & Jiang, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.070 · Cited by 190 · see citing works
Self-citationRosenholm, J. M., Peuhu, E., Bate-Eya, L. T., Eriksson, J., Sahlgren, C., & Lindén, M. (2010) · Small · doi:10.1002/smll.200902355 · Cited by 186 · see citing works
Joshi, B. H., Plautz, G. E., & Puri, R. K. (2000) · PubMed · Cited by 185 · see citing works
Han, L., Huang, R., Liu, S., et al. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100185f · Cited by 182 · see citing works
Self-citationKono, K., Ozawa, T., Yoshida, T., Ozaki, F., Ishizaka, Y., Maruyama, K., Kojima, C., Harada, A., & Aoshima, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.045 · Cited by 168 · see citing works
Kim, T.-H., Mount, C., Gombotz, W. R., & Pun, S. H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.06.004 · Cited by 165 · see citing works
Effect of Poly(ethylene glycol) Length on the in Vivo Behavior of Coated Quantum Dots
Daou, T. J., Li, L., Reiß, P., Josserand, V., & Texier, I. (2009) · Langmuir · doi:10.1021/la8035083 · Cited by 154 · see citing works
Madhankumar, A. B., Slagle‐Webb, B., Wang, X., Yang, Q. X., Antonetti, D. A., Miller, P. A., Sheehan, J. M., & Connor, J. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0853 · Cited by 124 · see citing works
Tumor-Targeted Drug Delivery with Aptamers
Zhang, Y., Hong, H., & Cai, W. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797189547 · Cited by 118 · see citing works
Huang, I., Sun, S.-P., Cheng, S., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0884 · Cited by 118 · see citing works
Nanomedicine: Techniques, Potentials, and Ethical Implications
Ebbesen, M., & Jensen, T. G. (2006) · Journal of Biomedicine and Biotechnology · doi:10.1155/jbb/2006/51516 · Cited by 117 · see citing works
Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles
Hong, M., Zhu, S., Jiang, Y., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.024 · Cited by 106 · see citing works
Brain-Targeting Mechanisms of Lactoferrin-Modified DNA-Loaded Nanoparticles
Huang, R., Ke, W., Han, L., Liu, Y., Shao, K., Ye, L., Lou, J., Jiang, C., & Pei, Y. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.104 · Cited by 91 · see citing works
Self-citationFillmore, H. L., Shultz, M. D., Henderson, S. C., et al. (2011) · Nanomedicine · doi:10.2217/nnm.10.134 · Cited by 89 · see citing works
Analysis of interleukin‐13 receptor α2 expression in human pediatric brain tumors
Kawakami, M., Kawakami, K., Takahashi, S., et al. (2004) · Cancer · doi:10.1002/cncr.20470 · Cited by 87 · see citing works
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
Candolfi, M., Xiong, W., Yagiz, K., Liu, C., Muhammad, A. K. M. G., Puntel, M., Foulad, D. S., Zadmehr, A., Ahlzadeh, G. E., Kroeger, K. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008261107 · Cited by 87 · see citing works
Growth of hydroxyapatite in a biocompatible mesoporous ordered silica
Díaz‐Cuenca, A., López, T., Manjarrez-Marmolejo, J., et al. (2006) · Acta Biomaterialia · doi:10.1016/j.actbio.2005.12.006 · Cited by 86 · see citing works
Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Kolhatkar, R. B., Lote, A. R., & Khambhati, H. (2011) · Current Drug Discovery Technologies · doi:10.2174/157016311796799044 · Cited by 62 · see citing works
Huang, R., Liu, S., Shao, K., et al. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/26/265101 · Cited by 61 · see citing works
Self-citationKioi, M., Seetharam, S., & Puri, R. K. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2131 · Cited by 58 · see citing works
Molecular targeting with recombinant cytotoxins of interleukin-13 receptor α2-expressing glioma
Mintz, A., Gibo, D. M., Madhankumar, A. B., et al. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02700026 · Cited by 36 · see citing works
Ulasov, I. V., Tyler, M. A., Han, Y., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.146 · Cited by 33 · see citing works
Protein- and DNA-Based Active Immunotherapy Targeting Interleukin-13 Receptor Alpha2
Mintz, A., Gibo, D. M., Madhankumar, A. B., et al. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0462 · Cited by 18 · see citing works
Zhang, B., Liu, J.-J., Pei, D., Yang, Z., Di, J., Chen, F., Li, H., Xu, W., Wu, Y.-P., & Zheng, J.-N. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.0984 · Cited by 17 · see citing works
cDNA clone, prokaryotic expression and purification of human interleukin-13 receptor {alpha}2 chain
Yu, W., Su, Z., Wu, Z. B., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0566-6 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110 · see citing works
- Authors
- Wang, Y., Shi, W., Song, W., Wang, L., Liu, X., Chen, J., & Huang, R.
- Affiliations
- Fudan University (CN)
- Affiliated Hospital of Nantong University (CN)
- Corresponding author
- Chen, Jian
- Huang, Rongqin
- Venue
- Journal of Materials Chemistry
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 22
- Issue
- 29
- Pages
- 14608
- ISSN
- 0959-9428 (ISSN-L)
- 1364-5501
- OpenAlex
- W1979246285
- Cited by
- 46
- References
- 35
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 3 · 2018: 6 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 6 · 2013: 6
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Materials Chemistry (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Materials Chemistry › Mesoporous Materials and Catalysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mesoporous silica nanoparticles, peptide-modified nanoparticles, interleukin-13 receptor, doxorubicin delivery, receptor-mediated drug delivery, PEGylation, hydrophobic anticancer drugs, U251 cells, targeted chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
